Top-Rated StocksTop-RatedNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $11.90 -0.10 (-0.83%) (As of 02:58 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Roivant Sciences alerts: Email Address About Roivant Sciences Stock (NASDAQ:ROIV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Roivant Sciences alerts:Sign Up Key Stats Today's Range$11.84▼$12.1750-Day Range$10.17▼$12.5052-Week Range$8.24▼$13.24Volume4.29 million shsAverage Volume5.75 million shsMarket Capitalization$8.79 billionP/E Ratio2.35Dividend YieldN/APrice Target$17.39Consensus RatingModerate Buy Company OverviewRoivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More… Kamala Harris To Tank the Market? (Ad)URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Click here now to see how to protect yourself. Roivant Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 71st PercentileRoivant Sciences scored higher than 71% of companies evaluated by MarketBeat, and ranked 333rd out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoivant Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Roivant Sciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Roivant Sciences are expected to grow in the coming year, from ($1.14) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is 2.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is 2.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.29.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.62% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Roivant Sciences has recently decreased by 6.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.62% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Roivant Sciences has recently decreased by 6.55%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.61 News SentimentRoivant Sciences has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search Interest27 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 238% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ROIV Stock News HeadlinesOrganon to Buy Roivant's Dermatology Unit For Up to $1.2 BillionSeptember 18 at 7:02 PM | msn.comRoivant Sciences: Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1%September 18 at 7:02 PM | finanznachrichten.deWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 19, 2024 | Porter & Company (Ad)Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2BSeptember 18 at 7:02 PM | finance.yahoo.comRoivant Flips a Skin Drug to OrganonSeptember 18 at 10:59 AM | barrons.comOrganon To Buy Dermavant For Around $1.2 BlnSeptember 18 at 8:59 AM | markets.businessinsider.comOrganon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 BillionSeptember 18 at 8:59 AM | marketwatch.comOrganon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%September 18 at 7:30 AM | globenewswire.comSee More Headlines ROIV Stock Analysis - Frequently Asked Questions How have ROIV shares performed this year? Roivant Sciences' stock was trading at $11.23 at the start of the year. Since then, ROIV stock has increased by 7.5% and is now trading at $12.07. View the best growth stocks for 2024 here. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) issued its earnings results on Thursday, August, 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.33. The business's revenue for the quarter was up 155.1% compared to the same quarter last year. Who are Roivant Sciences' major shareholders? Top institutional shareholders of Roivant Sciences include Rubric Capital Management LP (3.11%), DME Capital Management LP (0.65%), BlackBarn Capital Partners LP (0.42%) and Troluce Capital Advisors LLC (0.40%). Insiders that own company stock include Pharma Technologies Ltd Dexcel, Sciences Ltd Roivant, Svf Investments (Uk) Ltd, Vivek Ramaswamy, Financial Lp Qvt, Keith S Manchester, Matthew Gline, Global Investors Lp Viking, Eric Venker, Richard Pulik and Rakhi Kumar. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today9/19/2024Next Earnings (Estimated)11/11/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees860Year FoundedN/APrice Target and Rating Average Stock Price Target$17.39 High Stock Price Target$23.00 Low Stock Price Target$12.50 Potential Upside/Downside+44.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.06 Trailing P/E Ratio2.37 Forward P/E RatioN/A P/E GrowthN/ANet Income$4.35 billion Net Margins2,991.75% Pretax Margin2,937.20% Return on Equity-17.23% Return on Assets-15.10% Debt Debt-to-Equity Ratio0.05 Current Ratio27.91 Quick Ratio27.91 Sales & Book Value Annual Sales$158.30 million Price / Sales56.04 Cash FlowN/A Price / Cash FlowN/A Book Value$7.99 per share Price / Book1.50Miscellaneous Outstanding Shares738,722,000Free Float704,741,000Market Cap$8.87 billion OptionableOptionable Beta1.25 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ROIV) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this dif...InvestorPlace | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.